4 competitive national public projects led: ISCIII and MICINN
1 private project led
9 clinical studies led
1 competitive HR contract
6 publications
IF: 34.90
Q1 publications: 2 (33%)
D1 publications: 1(17%)
Project evaluator in national associations: 1 PI
Member of editorial committees: 1 PI
Milestones
Start of two National Plan research projects funded by the ISCIII (AES 2023): PI23/01302 IP. Dr. María Álvarez and PI23/01819 PI. Dr. María Jesús del Cerro.
International extension of the patent "Pharmaceutical composition for preventing or treating bronchopulmonary dysplasia by the intravenous route in repeated doses" PCT/ EP2024/057670.
Start of three privately funded clinical trials: TREPaed (sponsor: AOP ORPHAN pharmaceuticals GMBH), AV-101-002 and AV-101-003 (sponsor: AEROVATE THERAPEUTICS, INC) IP. Dr. María Jesús del Cerro.
Cerro MJD, Ormazábal IG, Gimeno A, Álvarez M, López P, Avila A, Arruza L, González C, Labrandero de Lera C, Lozano M, Moreno L, Melen G, Ramírez M, Saldaña N, Pavón A, Vento M, "PULMESCELL" I. Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up. Cytotherapy. 2024;26(6): 632 - 640. DOI:10.1016/j.jcyt.2024 .02.028.
Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, del Cerro MJ, d'Alteroche L, Rautou PE, Bañares R, Albillos A, VALDIG C. Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort. J Hepatol. 2024;DOI:10.1016/j.jhep.2024.09.005.
